Participated · Series A · Mar 2026

Founded in 2021 and headquartered in Long Beach, California, Vast is building the Haven line of modular commercial space stations designed for microgravity research, in-space manufacturing, and astronaut habitation. The company flew its Haven Demo spacecraft in 2025 to validate key technologies and is currently integrating Haven-1, slated to launch in 2027 as the world’s first commercial space station. A larger Haven-2 platform is planned to help replace the International Space Station around 2030, and Vast has also secured a private astronaut mission to the ISS through NASA. Vast pursues a vertically integrated manufacturing model that it claims has cut primary structure costs by roughly 10× compared with traditional station programs. Its roadmap ultimately includes habitats for lunar and Martian applications, aligning with a vision of enabling billions of people to live and work in space. Including the latest round, more than $1 billion has been invested in the company’s technology and facilities, providing significant capital to scale engineering, expand infrastructure, and grow headcount.

Participated · Series A · Apr 2024

Medmain develops and provides PidPort, an AI‑powered cloud platform for digital pathology that supports slide digitization, remote diagnostic support, multi‑facility conferences, education, research, and quality control. The company says it accelerates pathology AI development via a proprietary platform using transfer learning. PidPort is already used across a range of clinical and research settings. Medmain plans to enhance functionality, strengthen integration with surrounding systems, and improve usability. The company will invest in infrastructure for digitalization, expand its sales organization, pursue regulatory approval for its pathology AI, and prepare for international expansion. With this round the company reports total equity funding of $18 million and is based in Fukuoka, Japan. Medmain builds and operates PidPort, a cloud system that integrates digitalization of pathology slides with AI-powered analysis and remote-diagnostic workflows. Its platform connects facilities for telepathology, supports consultations, multi-facility conferences, education, and research, and is already used by multiple medical customers. The company says its core pathology AI uses transfer learning to accelerate model development and can detect cancer across multiple organs. Medmain plans to continue enhancing PidPort’s functionality and integrations to improve usability and broaden adoption. It will invest further in software and AI development, digitization equipment, sales expansion, and pursuing medical-device approval. The company positions itself to address rising pathology workload and chronic staffing shortages through digital transformation of pathology services. Medomain develops and provides PidPort, a digital pathology support solution that leverages deep learning and the company’s proprietary image-processing techniques to enable fast, high-accuracy pathology diagnoses. The product was developed in collaboration with Kyushu University’s medical faculty and Kyushu University Hospital, using supercomputing resources for accelerated AI training. An alpha version shipped in winter 2018 and a formal release followed in February 2020; the company has conducted joint research with medical institutions nationwide. Medomain was founded in January 2018 as the first startup from Kyushu University’s entrepreneurship program. In the current financing it received ¥300 million from PACS provider PSP and entered a capital-and-business alliance; prior to this it raised ¥1.1 billion in August 2020, bringing cumulative funding to about ¥1.5 billion. Medomain and PSP plan to integrate Medomain’s pathology diagnosis technologies into PSP’s infrastructure and services and to jointly develop new systems such as a pathology cloud PACS.

Participated · Series A · Oct 2023

Aibuild is a London-based software company that uses artificial intelligence to automate and optimize additive manufacturing workflows. Developed from more than a decade of research, its hardware-agnostic platform connects digital designs directly to physical production, integrating with diverse 3D printers, materials and manufacturing scenarios. By replacing manual, error-prone steps with AI that understands real production constraints, the system delivers automation, in-process quality assurance and higher operational efficiency. The solution targets manufacturers in aerospace, space, automotive and energy sectors that face complex production challenges. With its latest funding the company will enhance automation and quality-assurance features, expand integrations across machine and material ecosystems, and scale globally. Financial terms of the new round were not disclosed, and no revenue or user metrics were provided in the article.

Participated · Series B · Sep 2022

Ajira develops behavior-recognition AI and commercializes it as the AI security product 'AI Security asilla'. Headquartered in Machida, Tokyo, the company has been selling asilla for about a year with deployments in large commercial and complex facilities, hospitals, educational institutions, railways, airports and other public and private infrastructure. Asilla operates on existing cameras, can process up to 50 camera feeds per server in its enterprise plan, and uses a patented "anomaly detection" approach to identify precursors to incidents. The product provides local, secure 24/7 monitoring and instant notifications (within one second) when abnormal behavior is detected. Planned feature updates include fire/flame detection and unattended-object detection to broaden use cases in facility and transportation security. Financially, Ajira has completed a Series C extension bringing the round to ¥760M to date and has raised ¥1.7B in total funding. Asilla has developed proprietary behavior-recognition AI and sells an AI security system called AI Security asilla that analyzes existing camera feeds to detect abnormal or suspicious behavior. The product can run locally, process up to 50 cameras per server, and uses a patented “discomfort detection” method for early warning; it is deployed in complex facilities, commercial sites, hospitals, educational institutions and transportation infrastructure across Japan. The company emphasizes low initial cost by leveraging existing cameras and a secure, local network architecture to avoid external video leakage. Asilla is expanding its product lineup and sales network to grow revenue by entering markets beyond its traditional customers. Management plans to strengthen the asilla sales organization, continue evolving the core AI technology, and enhance corporate governance to build a scalable business foundation. The company is headquartered in Machida, Tokyo, and is led by CEO Daisuke Kimura. Asilla develops proprietary behavioral-recognition AI for video analytics and has released a facility-targeted AI security system called “Asilla.” The company reports growing deployments in large commercial facilities and office buildings since the product launch this year. It positions the system to address security industry labor shortages and improve safety, and it says it intends to pursue global expansion in the future. Asilla plans to use new capital and partnerships to strengthen its sales channels, advance its behavior-recognition models, and enhance corporate governance. The company was founded on June 1, 2015, and is headquartered in Machida, Tokyo. Reported corporate details include paid-in capital of ¥56,125 thousand.

Participated · Equity · May 2021

Oxford Nanopore Technologies Limited announced it received £195 million in funding on May 4, 2021. The financing was an equity round raised at a post-money valuation of £2.48 billion. The transaction included participation from new investors M&G Investment Management, Nikon Corporation, Temasek Holdings, and Wellington Management for £125 million, and existing investors including IP Group Plc for £70 million. M&G Investment Management invested £35 million, and IP Group Plc invested £18.7 million to hold a 14.5% stake in the company. The announced investor group comprised M&G Investment Management, Nikon Corporation, Temasek Holdings, Wellington Management Group LLP, IP Group Plc and other investors. Oxford Nanopore Technologies is described in the article as a sequencing unicorn and develops gene-sequencing devices. The piece reports the company recently raised $105.9M in new cash. That fundraising provided liquidity that allowed some investors to recoup cash. Investors associated with Neil Woodford’s former fund are explicitly mentioned as having recouped some cash. The coverage frames the transaction as offering relief for Woodford-associated funds. The article states the company closed the fundraising transaction. Oxford Nanopore develops portable, real-time long-read DNA/RNA sequencing devices (MinION, GridION, PromethION, Flongle) and uniquely enables direct RNA sequencing and modified-base detection. MinION has been commercially available since 2015 and is used by scientists in more than 70 countries. PromethION is a high-throughput, modular system—article notes >150Gb per PromethION flow cell in early 2018 and customers producing 70–100Gb per flow cell—enabling sub-$1,000 human genomes on long-read data. The company emphasizes simple sample preparation (5–10-minute kit, VolTRAX) and is developing single-test adapters (Flongle) and a forthcoming smartphone sequencer, SmidgION. Oxford Nanopore is expanding global operations with commercial presence in New York, US Cambridge, China, Japan, France and Germany, and new operations opening in Shanghai and San Francisco; new headquarters recently opened in Oxford. The company is scaling manufacturing and R&D to grow applications from infectious-disease surveillance and precision medicine to food- and water-safety monitoring and environmental science. Oxford Nanopore Technologies develops nanopore-based DNA/RNA sequencing platforms, led by the portable MinION. Its product portfolio includes the MinION, high-throughput PromethION, the VolTRAX automated sample/library preparation device, and the mobile-phone compatible SmidgION in its pipeline. The MinION has been commercially available since 2015 and is used by a community in more than 50 countries for real-time, long-read sequencing in lab and field settings. Oxford Nanopore also offers analysis solutions through Metrichor to make analyses accessible to non-experts. The company plans to expand commercial operations—particularly in Asia—add production and sales & marketing resources, and continue rapid improvement of existing products and development of its pipeline. Following the latest placement, the company has raised a total of £351 million. Oxford Nanopore Technologies develops and commercialises nanopore-based electronic systems for single-molecule analysis of DNA, RNA and proteins. Its product portfolio includes the handheld MinION, the high-throughput PromethION, the GridION system, and supporting tools such as VolTRAX for sample preparation and Metrichor for cloud-based real-time analysis. MinION was made commercially available in 2014 and registration has opened for the PromethION Early Access programme. The company focuses on real-time data streaming, improved simplicity, efficiency and scalability of workflows, and low total cost-of-ownership across scientific, medical, crop science, security and environmental applications. Oxford Nanopore raised new funding to support improvements to existing products and services, further develop and expand its pipeline, and expand manufacturing and commercial activities. The fundraising increases the company’s total funds raised to £251 million.